Phesgo and Tecentriq Performance and Approvals
Ophthalmology: Excellent Vabysmo launch continues
Double-digit US market share in nAMD and mid single-digit in DME*
CHFM
500
400
300
200
100
YoY CER growth
>500%
0
Q122
Q2 22
Q3 22
Q4 22
Q123
IUS Europe International
Japan
Q1 update
Vabysmo
MIAMI
Roche
Angiogenesis
2023
ARVO
2023
• US: Strong uptake with switches primarily from aflibercept; use in
naive patients further accelerating
• >860k vials shipped globally in first 14 months of launch
• Positive Ph III (BALATON/COMINO) results for Vabysmo in RVO
presented at Angiogenesis 2023
•
⚫ Ph Ill post-hoc analyses in nAMD & DME indicating greater retinal
drying for Vabysmo vs aflibercept presented at ARVO 2023 (23-27 April)
Susvimo
• Positive Ph III (PAGODA/PAVILLION) results for Susvimo in DME/DR
presented at Angiogenesis 2023
Outlook 2023
•
Vabysmo: Continued growth and market share gains in nAMD & DME
nAMD=neovascular age-related macular degeneration; DME-diabetic macular edema; RVO-retinal vein occlusion; DR-diabetic retinopathy; *Based on February 2023 patient claims data; Eylea (aflibercept) is a registered
trademark/product of Regeneron
30
50View entire presentation